ABSTRACT INTRODUCTION. *Diana Feier 1, *Monica Lupsor Platon 1,2, Horia Stefanescu 1,3, Radu Badea 1,2
|
|
- Gerard Skinner
- 6 years ago
- Views:
Transcription
1 Transient Elastography for the Detection of Hepatocellular Carcinoma in Viral C Liver Cirrhosis. Is there something else than Increased Liver Stiffness? *Diana Feier 1, *Monica Lupsor Platon 1,2, Horia Stefanescu 1,3, Radu Badea 1,2 1) Iuliu Hatieganu University of Medicine and Pharmacy; 2) Medical Imaging Department 3) Hepatology Department Regional Institute of Gastroenterology and Hepatology Cluj-Napoca, Romania Address for correspondence: Horia Stefanescu, MD, PhD Regional Institute of Gastroenterology and Hepatology Croitorilor Str, Cluj-Napoca, Romania hstefanescu@umfcluj.ro ABSTRACT Background & Aims: Liver stiffness (LS) is increased in liver cirrhosis, higher values being associated with complications, among them the development of hepatocellular carcinoma (HCC). However, LS values alone cannot accurately differentiate patients with HCC. Therefore, our aim was to study the performance of LS measurement data and common biomarkers for the detection of HCC in HCV related liver cirrhosis. Methods: We performed a case matching study comparing HCV cirrhotic patients with and without HCC (72 in each group) that were identical in terms of sex, age, BMI and duration of HCV infection. All patients underwent LS measurement, endoscopy, liver imaging and liver function tests. A multiple regression analysis was performed and a HCC detection model was calculated, which was further validated in another group of 40 HCV infected cirrhotics, of whom 52% had HCC. Results: In the HCC group, LS was significantly higher (42 vs 27 kpa, p<0.0001). In the multivariate analysis higher values of LS, alanine-aminotransferase (ALAT), alpha-fetoprotein (AFP) and interquartile range (IQR) of LS measurements were independently associated with the presence of HCC (p< for all parameters; Odds Ratios of 8.27, 1.01, 1.04 and 1.16, respectively). The detection model combining the four variables showed a good diagnostic performance in both training and validation groups, with AUROCs of 0.86 and 0.8, respectively. All variables were also positively correlated with tumor size. Conclusion: In HCV related cirrhosis, HCC is associated with increased LS and IQR values and high ALAT and AFP levels. By combining these four parameters into a regression model, liver cancer may be noninvasively predicted with good accuracy. Key words: liver cirrhosis hepatocellular carcinoma liver stiffness interquartile range detection model. Received: Accepted: *These authors contributed equally to the study INTRODUCTION Early detection of hepatocellular carcinoma (HCC) in patients with chronic hepatitis C virus (HCV) infection represents an emerging health problem. The growing incidence of HCV infection, together with continuous improvements in the clinical management of patients have led to an increasing prevalence of liver cirrhosis, which is the most important pathway towards developing HCC. These patients are the perfect candidates for HCC surveillance, having an annual incidence of HCC ranging between 4.1 and 7% [1]. The prognosis of patients with liver cirrhosis and HCC is strictly related to the liver residual function and tumour size, as stated and extensively validated by the BCLC criteria [2]; thus, non-invasive early detection of HCC is of major importance. Multiple parameters widely available in routine clinical practice were proposed for the detection of early HCC in patients with well-preserved liver function and various algorithms emerged for the diagnosis and follow-up of patients with HCV liver cirrhosis [3, 4]. Some of these models pointed out the individual role of increased liver stiffness (LS) measurements and serological markers as predictive biomarkers of HCC [5], but none of the studies evaluated the combined role of these main predictors. Transient elastography (TE) is an imaging technique that measures LS under the assumption of pure elasticity of the
2 284 Feier et al tissue [6]. Transient elastography accurately estimates and stages liver fibrosis, so that it is considered a surrogate for liver biopsy from this point of view. Transient elastography has been extensively validated over the last years, mainly in patients with chronic hepatitis C and it has been proved that its best accuracy is for detecting liver cirrhosis [7]. In the setting of liver cirrhosis, increased LS is associated with episodes of decompensation (high grade oesophageal varices - EV and/or bleeding, development of ascites) as well as with the presence of HCC [8], meaning that increased LS value alone cannot be an accurate predictor for HCC. The main drawbacks of TE are the technique difficulties in evaluating obese patients and the overestimation of liver fibrosis stage due to inflammation [9-13], central venous pressure [14], or cholestasis [15]. Transient elastography appears to be also influenced by the confounding effects resulting from attenuation and propagation of the acoustic waves in visco-elastic materials [11]. The aim of the present study was to study the performance of LS measurement data and of common biochemical parameters for the diagnosis of HCC in HCV related liver cirrhosis. MATERIAL AND METHODS Patients A cohort of consecutive patients previously diagnosed with HCV liver cirrhosis (either biopsy proven, or having unequivocal clinical, biological and imaging features) was retrospectively included in the study according to following criteria: age between 18 and 80 years, positive anti-hcv antibodies for at least 6 months, positive HCV RNA and compensated disease (Child-Pugh A or B with no ascites). All patients were naïve for the antiviral treatment. We excluded from the study patients with other etiology of chronic liver diseases such as: hepatitis B or HIV coinfection, ethanol induced or autoimmune liver disease, Wilson s disease, hemochromatosis or α1-antitripsin deficiency. They were matched by sex, age, BMI and years of HCV infection with another cohort of patients having early and very early HCC (BCLC class 0 or A). The same inclusion criteria were used as far liver cirrhosis was concerned. All HCC patients were inside the Milan criteria, meaning a single tumor of 5 cm or less in diameter, or no more than three nodules, each 3 cm or less in diameter [16, 17]. The two cohorts were compared in a case-matching manner and formed together the study group. The validation group consisted of another set of consecutive HCV patients having either liver cirrhosis alone or associated with early HCC. They were prospectively included using the same inclusion criteria as the study group, in order to validate the findings that emerged from the previous analysis. In the day of their participation in the study, a blood sample was obtained from all patients after 8 hours of overnight fasting for routine biomarkers: aspartate aminotransferase (ASAT), alanine aminotransferase (ALAT), gama-glutamyltranspeptidase (GGT), alkaline phosphatase (AP), total bilirubin, platelets count, and alpha-fetoprotein (AFP). On the same day, TE and imaging investigations were performed for assessing the presence of focal lesions. Patients in the HCC group were eventually excluded, if six months after their participation in the study, they exceeded the Milan criteria (either because of the size, or the number of the focal lesions) at a follow-up ultrasound evaluation. All patients also underwent oesophagoscopy for the assessment and grading of EV either during current admission, or in the previous 6 months interval. When present, EV were graded according to their size as follows: (i) grade 1: small, straight EV; (ii) grade 2: enlarged, tortuous EV occupying less than one third of the lumen; and (iii) grade 3: large, coil-shaped EV occupying more than one third of the lumen. The study was designed in full accordance with the Declaration of Human Rights (Helsinki, 1975) and its further revisions and was previously approved by the Hospital Ethics Committee. All patients gave their written informed consent before enrolling into the study. Liver stiffness measurement Liver stiffness measurements were performed in the right liver lobe using one-dimension transient (impulsional) elastography (FibroScan, Echosens, Paris, France) following the technical background and examination procedure as previously described [18]. Liver stiffness measurement was performed only after ultrasound guidance, in order to avoid the presence of focal liver lesions into the acquisition window. The medium probe was used for all patients. The results were expressed in kilopascals (kpa). The median value of 10 successful measurements was kept as a representative of the LS, according to the manufacturer s recommendations and previous evidence [19]. The success rate was calculated as the number of validated LS measurements divided by the number of total measurements. Only examinations with a success rate of at least 60% were further analysed [12]. Since we wanted to fully investigate the influence of stiffness related parameters, the interquartile range (IQR) lower than 30% of the median value was not considered an exclusion criteria, as previous studies suggested [20, 21]. All LS measurements were performed by experienced operators (DF, ML), with more than 2,000 examinations performed at the time of the study in patients with chronic liver diseases. Statistical analysis Mean LS values for the two groups were compared and introduced in a regression model of diagnosis. Data was analysed using MedCalc package for Windows. Data in text and tables are reported as mean (95%CI) or percentage (%). Demographic variables were assessed using descriptive statistics. Differences in mean values were tested using the t-test. The predictive value of biochemical and imaging parameters on HCC diagnosis was investigated through uniand multivariate regression analysis. Variables that showed a significant relationship (p<0.05) with the presence of HCC in univariate analysis were included in multivariate regression analysis, in order to evaluate their simultaneous influence. We computed the model s R-squared, the standardized and unstandardized weights, partial correlation coefficients and the p-values for all the variables included in the analysis. The relationship between different parameters and tumor size
3 Sero-elastographic detection model for HCC in HCV related cirrhosis 285 was tested through non-parametric Spearman correlation coefficients (r). The diagnostic performance of the LS and the regression model were assessed using the receiver operating characteristic (ROC) curves analysis. Optimal cut-off values were chosen by using a common optimization step that maximized the Youden index for predicting HCC. The sensitivity (Se), specificity (Sp), positive predictive value (PPV), negative predictive value (NPV) and likelihood ratios (LR) were computed from the same data, without further adjustments. A p value of less than 0.05 was considered to indicate statistical significance. RESULTS Each cohort of the case-matching study consisted of 72 HCV cirrhotic patients, with or without HCC nodules. Another 40 HCV liver cirrhosis patients were included in the validation group. Clinical and biochemical characteristics of the study patients are summarized in Table I. Liver stiffness values in the study population In the case-matching group LS values ranged from 23 to 75 kpa, with a mean value of 27 kpa in patients without HCC, significantly lower than the mean LS value in those with HCC - 42 kpa (p<0.001), as shown in Fig. 1. Liver stiffness alone showed a poor performance for the diagnosis of HCC, as it results from the ROC curve analysis (Fig. 2A). Regression analysis for HCC detection In the univariate analysis ALAT, AP, GGT, platelets count, AFP, large oesophageal varices, LS and IQR were statistically significantly different in patients with HCC vs those without (Table I). In the multiple regression analysis, only four variables statistically correlated with the presence of HCC: LS, IQR, AFP and ALAT, of which LS had the highest odds ratio (OR) (Table II). The four parameters together explained 64.5% of the variance of the HCC (R2=0.645, p<0.0001) and uniquely explained 45.45% of the amount of R2, with LS making the largest unique contribution; the difference of 19.05% (64.5% - Fig. 1. Box plots of liver stiffness values according to HCC presence. The top and the bottom of the boxes are the first and third quartiles, respectively. The length of the box thus represents the interquartile range within which 50% of the values were located. The line through the middle of each box represents the median. The error shows the minimum and maximum values (range) %) was accounted for by the joint contribution of the four parameters. Using the coefficients obtained in the regression analysis, the prediction model computed from this study can be expressed as follows: Regression equation (LogitHCC)=1.92*LS+1.49*IQR+0.04 *AFP+0.02*ALAT Analysing the performance of the predictive model for assessing the presence of HCC in the study population using the ROC curve method, we obtained a cut-off value of 0.5, a probability of 86% that a randomly selected individual from the HCC group has a test result indicating higher suspicion than that for a randomly chosen individual from the negative group (Fig. 2B, Table III). We also analysed the relationship between the HCC size and each parameter included in the regression equation and we found a high positive correlation for LS (r=0.77, p<0.0001) and IQR (r=0.71, p<0.0001) and a moderate but significant correlation with the values of AFP (r=0.42, p=0.03). Fig. 2. Comparative analysis of LS alone and prediction model computed based on the regression equation for assessing the presence of HCC in the study population A: Receiver operating characteristic (ROC) curve for LS as unique predictor of HCC. B: Receiver operating characteristic (ROC) curve for the regression model in HCC assessment.
4 286 Feier et al Table I. Baseline characteristics of the patients included in the study* Patients Case-matching group characteristics Liver cirrhosis without HCC Liver cirrhosis with HCC p Validation group Nr Age ( ) ( ) Male sex 48.61% 48.61% 1 54% BMI ( ) ( ) ASAT (U/l) ( ) ( ) ALAT (U/I) ( ) ( ) < AP (U/I) ( ) ( ) < GGT (U/I) ( ) ( ) < Total bilirubin (mg/dl) 0.98 ( ) 1.73 ( ) < Platelets (10 3 /mm 3 ) ( ) ( ) < AFP (U/I) ( ) 119( ) Presence of HCC Nr. of patients (%) 0 (0) 72 (100) 21(52.5) Nr. of nodules Mean diameter (mm) ( ) Oesophageal varices grade 1 (%) 14 (19.44) 9 (12.5) (22.5) grade 2,3 (%) 4 (5.55) 10 (13.88) 14 (35) Liver stiffness measurement LS (kpa) ( ) ( ) < IQR% ( ) ( ) Success rate 86 (91-100) (81-100) * Data are expressed as absolute numbers, percentage or mean values. CI - confidence interval, ASAT - aspartate aminotransferase, ALAT - alanine aminotransferase, AP alkaline phosphatase, GGT - gamma-glutamyltranspeptidase, AFP - alpha-fetoprotein, LS - liver stiffness, IQR - Interquartile range Table II. Parameters independently associated with presence of HCC Main OR* 95%CI Coefficient Std. Error P predictors LSM IQR ALAT AFP OR Odds Ratio, CI - confidence interval, Std. Error- Standard Error, LS - liver stiffness, IQR - Interquartile Range, ALAT - alanine aminotransferase, AFP alpha-fetoprotein * OR for the independent variables gives the relative amount by which the odds of HCC increase or decrease when the value of the independent variable is increased by 1 unit Validation of the HCC model In the validation group, the mean LS value was 37 kpa, ranging between 23 and 75 kpa. Assessing the performance of the predictive model in the validation population and plotting the ROC curve for the prediction of HCC, using the same cut-off value, we still obtained a good AUROC and comparable Se, Sp, PPV and NPV figures (Fig. 3, Table III). Fig. 3. Validation (ROC curve analysis) of the prediction model in a new set of patients. DISCUSSION The present paper confirms the current knowledge that increased LS, AFP and serum transaminases are predictors of the presence of HCC in HCV liver cirrhosis patients. Besides
5 Sero-elastographic detection model for HCC in HCV related cirrhosis 287 Table III. The diagnostic performance of the regression model for the prediction of HCC in the study group and the validation group. HCC vs no HCC study group HCC vs no HCC validation group Se (%) (95%CI) ( ) ( ) Sp (%) (95%CI) ( ) ( ) +LR LR PPV (%) NPV (%) AUROC (95%CI) 0.86 ( ) 0.80 ( ) Standard Error p < < Se -sensitivity, Sp - specificity, PPV- positive predictive value, NPV - negative predictive value, CI - confidence interval, +LR - Positive likelihood ratio, -LR - Negative likelihood ratio, AUROC - area under ROC curve, SE - standard error that, we demonstrated that increased IQR might be also a predictor for HCC, raising the question of a stiffness shadow generated by HCC into the cirrhotic liver. We also managed to compute a prognostic model based on regression analysis, that predicted the presence of HCC in both training and validation cohort with good accuracy. Liver stiffness measurement using TE is recognised as accurately assessing the stage of liver fibrosis in patients with chronic HCV infection [12, 18], recorded values increasing as the liver disease progresses, and the highest LS being specific for cirrhotic patients with associated HCC [10]. Therefore, it was thought that LS measurement might be a valuable noninvasive tool for assessing the presence of, or the risk of developing liver cancer. The first studies reported a cut-off value of 53.7 kpa as suggestive for the presence of HCC in HCV cirrhotic patients [10], especially if total serum bilirubin was higher than 1.0 mg/dl [20]. However, the proposed threshold was not independently validated, and ranged between 12.5 and 53.7 kpa in other reports [5, 20, 21]. In Foucher s study [10] the 53.7 kpa value was obtained from a subset of only 19 patients with HCC, and the Se% and Sp% were 37% and 87%, respectively, with PPV and NPV of 30% and 90%. In addition, the study population in all mentioned papers was heterogeneous (HBV, HCV and ethanol), whereas our study included only HCV patients. For all these reasons we chose to determine our own cut-off value (38.5 kpa). Optimal cut-off values were chosen by using a common optimization step that maximized the Youden index and Se, Sp, PPV and NPV were computed from the same data, without further adjustments. Nevertheless, LS assessed by magnetic resonance elastography is not associated with the development of HCC in subjects with compensated cirrhosis [22]. None of these studies have been designed to evaluate the accuracy of more predictive parameters, in addition to LS. Therefore, we analysed a series of simple and widely available biochemical parameters together with LS and the variance of the measurement (IQR) and we performed a logistic regression analysis. Between the investigated parameters, LS measurement is the most important predictor, as suggested by the squared partial correlation. Taking into account the cut-off values obtained for LS measurements alone, we can suggest that a LS greater than 38 kpa in an HCV infected cirrhotic patient is an important indicator to further investigate the presence of a liver tumour (OR=8.27). Another important and surprising parameter was the IQR percentage of LS measurements. An IQR greater than 39% of median LS value resulted in being a good indicator and an important predictor of HCC presence. Interquartile range represents the interval including 50% of patients above and below the median. According to the manufacturer s suggestion, the IQR/LS should be less than 30% of the median value [19]. Only a few studies investigated this issue, therefore the interpretation of results is derived more from personal experience and from the manufacturer s advice. However, even lower values (<20%) [23] have been proposed in order to obtain a better concordance with liver biopsy. If gross technical operation errors are eliminated, than an IQR value greater than 30% indicates that structure disintegration is present in the liver. By finding a significantly higher IQR value (39.15% vs %; p=0.001) in the HCC group, it means that this tissue unrest is due to the presence of HCC itself. It cannot be stated that HCC increases the LS because of its structure, as it is well known that liver cancer is a soft tumour [24]. More probably, it is the shear stress produced by the chaotic growth of the tumour inside of an already hard medium (the cirrhotic tissue) that induces the LS and the IQR increment. This finding supports the hypothesis of Mueller and Sandrin, according to which not only matrix but also pressure-associated conditions influence LS [25]. This inhomogeneous distribution of LS appears to generate a stiffness shadow, a finding that may have important clinical implications: if a certain patient with HCV cirrhosis, followed up by TE among other methods, suddenly develops an increase in LS median value, as well as in IQR, it may indicate the presence of HCC and may speed up the referral to other diagnostic techniques. In our study, the presence of HCC was associated with high ALAT values, as previously reported [26], an association stronger if the ALAT increase is persistent [27]. Surprisingly, we found no correlation between large (grade 2 and 3) EV and the presence of HCC, although it is known that the two conditions are usually associated and each of them predict a poor outcome of the other [28]. As a common practice, AFP is widely used for HCC diagnosis, despite its low sensitivity and specificity [29]. However, high AFP levels at baseline were associated with an increased risk for HCC in HCV infected patients [30]. In our study, increased AFP was an independent predictor of HCC presence, but not an important variable in the regression model. Our findings support the idea that each independent predictor, LS, IQR, ALAT and AFP, have a large role in the detection of HCC. The prognostic model is based on logistic regression, because this analysis finds the best fitting (yet biologically reasonable) model to describe the relationship between the outcome (HCC) and all independent variables. The four identified parameters predicted 64.5% of the HCC, with LS having the highest predictive power. The size and the direction of the relationship suggest that higher LS values are obtained for patients with HCC. The prognosis model using this formula had a good diagnostic performance, with an AUROC of 0.86 in the training set, and 0.8 in the validation one.
6 288 Feier et al The efficacy of a predictor should be assessed under ideal conditions, which we tried to reproduce in a case-matching study by assuring a homogeneous background noise in the two groups [31]. By trying to generate the same baseline conditions, we also overcame some of the critical aspects of case-control studies: the selection of cases, recall bias, and surveillance bias. Therefore, we enrolled only patients under surveillance according to the latest recommendations [2, 32] and with the same frequency. Additionally, we matched the patients according to age, sex, BMI and history oh HCV infection - because recent reports suggest a direct correlation between these parameters and the presence of HCC [33-36]. In this way, we could overcome the issue of BMI, which strongly determines the outcome of LS measurements [37]. To our knowledge, this is the first study that reports the combined role of LS measurement (median value and variance - IQR) and serum markers (AFP and ALAT) in the prediction of HCC in chronic HCV patients, with good performance. However, the most important finding of the study seems to be the increased IQR as a predictor of HCC presence. Since TE is a common examination in outpatient settings, the finding of an elevated LS value (e.g. >38 kpa, as our data suggest) as well as of an increased IQR during the follow-up of a patient with compensated liver cirrhosis may raise awareness for early HCC and may hasten the referral to confirmatory imaging techniques. This will not become a screening method, but will definitely improve the screening performance, by selecting the high risk patients for further confirmatory investigations. CONCLUSION In patients with HCV related cirrhosis, the presence of HCC is associated with increased LS and IQR values, as well as with high ALAT and AFP serum levels. Combining these four parameters into a model based on logistic regression analysis, liver cancer may be predicted with good accuracy. Stiffness changes, however, seem to be more complex, generating a shadow that might be characteristic for HCC, but this finding needs to be further investigated. Nevertheless, we believe that such an approach could be used to identify patients at high risk or, on the contrary, patients with no risk of HCC in order to limit the screening and decrease the number of useless procedures. Acknowledgements: This work was partially funded by the European Social Fund through the POSDRU 107/1.5/S/78702 Project. The authors would like to thank Dr. Bogdan Procopet for the stimulating discussions and valuable ideas that he offered during preparation of the manuscript. Conflicts of interest: None to declare. REFERENCES 1. Lok AS, Seeff LB, Morgan TR, et al. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology 2009;136: Bruix J, Sherman M; American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology 2011;53: Kanwal F, Hoang T, Kramer JR, et al. Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection. Gastroenterology 2011;140: e1. 4. Wang CH, Mo LR, Chang KK, Lin RC, Kuo JJ. A cohort study to investigate hepatocellular carcinoma risk in hepatitis C patients. Hepatogastroenterology 2011;58: Nahon P, Kettaneh A, Lemoine M, et al. Liver stiffness measurement in patients with cirrhosis and hepatocellular carcinoma: a case-control study. Eur J Gastroenterol Hepatol 2009;21: Sandrin L, Fourquet B, Hasqueoph JM, et al. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol 2003; 29: Friedrich Rust M, Ong MF, Martens S, et al. Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. Gastroenterology 2008;134: Masuzaki R, Tateishi R, Yoshida H, et al. Prospective risk assessment for hepatocellular carcinoma development in patients with chronic hepatitis C by transient elastography. Hepatology 2009;49: Tapper EB, Cohen EB, Patel K, et al. Levels of alanine aminotransferase confound use of transient elastography to diagnose fibrosis in patients with chronic hepatitis C virus infection. Clin Gastroenterol Hepatol 2012;10: e Foucher J, Chanteloup E, Vergniol J, et al. Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study. Gut 2006;55: Ganne-Carrie N, Ziol M, de Ledinghen V, et al. Accuracy of liver stiffness measurement for the diagnosis of cirrhosis in patients with chronic liver diseases. Hepatology 2006;44: Kettaneh A, Marcellin P, Douvin C, et al. Features associated with success rate and performance of FibroScan measurements for the diagnosis of cirrhosis in HCV patients: a prospective study of 935 patients. J Hepatol 2007;46: Lupşor M, Badea R, Stefănescu H, et al. Analysis of histopathological changes that influence liver stiffness in chronic hepatitis C. Results from a cohort of 324 patients. Gastrointestin Liver Dis 2008;17: Millonig G, Friedrich S, Adolf S, et al. Liver stiffness is directly influenced by central venous pressure. J Hepatol 2010;52: Millonig G, Reimann FM, Friedrich S, et al. Extrahepatic cholestasis increases liver stiffness (FibroScan) irrespective of fibrosis. Hepatology 2008;48: Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996;334: Singal A, Volk ML, Waljee A, et al. Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther 2009;30: Ziol M, Handra-Luca A, Kettaneh A, et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology 2005;41: Castera L, Forns X, Alberti A. Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol 2008;48: Akima T, Tamano M, Hiraishi H. Liver stiffness measured by transient elastography is a predictor of hepatocellular carcinoma development in viral hepatitis. Hepatol Res 2011;41:
7 Sero-elastographic detection model for HCC in HCV related cirrhosis Kuo YH, Lu SN, Hung CH. Liver stiffness measurement in the risk assessment of hepatocellular carcinoma for patients with chronic hepatitis. Hepatol Int 2010;4: Anaparthy R, Talwalkar JA, Yin M, Roberts LR, Fidler JL, Ehman RL. Liver stiffness measurement by magnetic resonance elastography is not associated with developing hepatocellular carcinoma in subjects with compensated cirrhosis. Aliment Pharmacol Ther 2011;34: Lucidarme D, Foucher J, Le Bail B, et al. Ratio interquartile range / median value of liver stiffness measurement is a key factor of accuracy of transient elastography (FIBROSCAN ) for the diagnosis of liver fibrosis. Hepatology 2007;46 Suppl:A Bruix J, Castells A, Bosch J, et al. Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure. Gastroenterology 1996;111: Mueller S, Sandrin L. Liver stiffness: a novel parameter for the diagnosis of liver disease. Hepatic Medicine: Evidence and Research 2010;2: Kobayashi M, Suzuki F, Akuta N, et al. Development of hepatocellular carcinoma in elderly patients with chronic hepatitis C with or without elevated aspartate and alanine aminotransferase levels. Scand J Gastroenterol 2009;44: Miyakawa K, Tarao K, Ohshige K, et al. High serum alanine aminotransferase levels for the first three successive years can predict very high incidence of hepatocellular carcinoma in patients with Child Stage A HCV-associated liver cirrhosis. Scand J Gastroenterol 2009;44: Chang CJ, Hou MC, Liao WC, Lee FY, Lin HC, Lee SD. Risk factors of early re-bleeding and mortality in patients with ruptured gastric varices and concomitant hepatocellular carcinoma. J Gastroenterol 2012;47: Zhang G, Ha SA, Kim HK, et al. Combined analysis of AFP and HCCR-1 as an useful serological marker for small hepatocellular carcinoma: a prospective cohort study. Dis Markers 2012;32: Tateyama M, Yatsuhashi H, Taura N, et al. Alpha-fetoprotein above normal levels as a risk factor for the development of hepatocellular carcinoma in patients infected with hepatitis C virus. J Gastroenterol 2011;46: Altman DG. Practical statistics for medical research. London: Chapman &Hall Gardner MJ, Altman DG. Gli intervalli di confidenza. Rome: Il pensiero scientifico editore European Association For The Study Of The Liver; European Organisation For Research And Treatment Of Cancer. EASL EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012;56: Walter SR, Thein HH, Gidding HF, et al. Risk factors for hepatocellular carcinoma in a cohort infected with hepatitis B or C. J Gastroenterol Hepatol 2011;26: Wang CH, Mo LR, Chang KK, Lin RC, Kuo JJ. A cohort study to investigate hepatocellular carcinoma risk in hepatitis C patients. Hepatogastroenterology 2011;58: Kanwal F, Hoang T, Kramer JR, et al. Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection. Gastroenterology 2011;140: Akiyama T, Mizuta T, Kawazoe S, et al. Body mass index is associated with age-at-onset of HCV-infected hepatocellular carcinoma patients. World J Gastroenterol 2011;17: Castéra L, Foucher J, Bernard PH, et al. Pitfalls of liver stiffness measurement: a 5-year prospective study of 13,369 examinations. Hepatology 2010;51:
Transient elastography in chronic viral liver diseases
4 th AISF POST-MEETING COURSE Roma, 26 Febbraio 2011 Transient elastography in chronic viral liver diseases CRISTINA RIGAMONTI, M.D., Ph.D. Transient elastography (TE): a rapid, non-invasive technique
More informationTransient elastography the state of the art
Transient elastography the state of the art Laurent CASTERA, MD PhD Department of Hepatology, Hôpital Beaujon, Clichy Université Paris-7, France White Nights of Hepatology, St Petersburg, Russia, june
More informationOriginal papers Med Ultrason 2013, Vol. 15, no. 2, Ioan Sporea, Iulia Raţiu, Simona Bota, Roxana Şirli, Ana Jurchiş
Original papers Med Ultrason 2013, Vol. 15, no. 2, 111-115 DOI: 10.11152/mu.2013.2066.152.is1ir2 Are different cut-off values of liver stiffness assessed by Transient Elastography according to the etiology
More informationNon-Invasive Testing for Liver Fibrosis
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Non-Invasive Testing for Liver Fibrosis John Scott, MD, MSc Associate Professor, University of Washington Associate Clinic Director, Hep/Liver Clinic, Harborview
More informationNON INVASIVE ASSESSMENT OF LIVER FIBROSIS : FIBROSCAN
NON INVASIVE ASSESSMENT OF LIVER FIBROSIS : FIBROSCAN M. Beaugrand Service d Hépatologied Hopital J. Verdier BONDY 93143 et Université Paris XIII MAINZ 21.09.2008 ASSESSMENT OF FIBROSIS : WHY? Management
More informationThe role of ARFI and APRI in diagnosis of liver fibrosis on patients with common chronic liver diseases
RESEARCH ARTICLE The role of ARFI and APRI in diagnosis of liver fibrosis on patients with common chronic liver diseases Objective: This study aimed to investigate the value of liver fibrosis assessment
More informationKeywords. Abstract. Introduction
A New and Simple Algorithm for the Noninvasive Assessment of Esophageal Varices in Cirrhotic Patients Using Serum Fibrosis Markers and Transient Elastography Horia Stefanescu 1,2, Mircea Grigorescu 1,
More informationWorldwide Causes of HCC
Approach to HCV Treatment in Patients with HCC JORGE L. HERRERA, MD, MACG UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE Worldwide Causes of HCC 60% 50% 40% 54% 30% 20% 10% 31% 15% 0% Hepatitis B Hepatitis
More informationReal-time elastography as a noninvasive assessment of liver fibrosis in chronic hepatitis C Egyptian patients: a prospective study
ORIGINAL ARTICLE Annals of Gastroenterology (2016) 29, 1-5 Real-time elastography as a noninvasive assessment of liver fibrosis in chronic hepatitis C Egyptian patients: a prospective study Lamiaa Mobarak
More informationInvasive. Sampling error. Interobserver variability. Nondynamic evaluation of
How to assess liver fibrosis Serum markers or FibroScan vs. liver biopsy? Laurent CASTERA & Pierre BEDOSSA Hôpital Beaujon, AP-HP, Clichy Université Paris-VII France 4 th Paris Hepatitis Conference, Paris,
More informationWorldwide Causes of HCC
Approach to HCV Treatment in Patients with HCC Mark W. Russo, MD, MPH, FACG Carolinas HealthCare System Charlotte Worldwide Causes of HCC 60% 50% 40% 30% 20% 10% 0% 54% 31% 15% Hepatitis B Hepatitis C
More informationScreening for HCCwho,
Screening for HCCwho, how and how often? Catherine Stedman Associate Professor of Medicine, University of Otago, Christchurch Gastroenterology Department, Christchurch Hospital HCC Global Epidemiology
More informationPROPOSTA DI UN NUOVO ALGORIMO PER LA DIAGNOSI ECOGRAFICA DELLE MALATTIE CRONICHE DEL FEGATO
PROPOSTA DI UN NUOVO ALGORIMO PER LA DIAGNOSI ECOGRAFICA DELLE MALATTIE CRONICHE DEL FEGATO A. Giorgio Direttore del servizio di Ecografia Interventistica Istituto Clinico S.Rita -IRCCS -Atripalda (Avellino)
More informationSurveillance for Hepatocellular Carcinoma
Surveillance for Hepatocellular Carcinoma Marion G. Peters, MD John V. Carbone, MD, Endowed Chair Professor of Medicine Chief of Hepatology Research University of California San Francisco Recorded on April
More informationTitle: The Baveno VI criteria for predicting esophageal varices: validation in real life practice
Title: The Baveno VI criteria for predicting esophageal varices: validation in real life practice Authors: Mafalda Sousa, Sónia Fernandes, Luísa Proença, Ana Paula Silva, Sónia Leite, Joana Silva, Ana
More informationEvaluation on liver fibrosis stages using the k-means clustering algorithm
Annals of University of Craiova, Math. Comp. Sci. Ser. Volume 36(2), 2009, Pages 19 24 ISSN: 1223-6934 Evaluation on liver fibrosis stages using the k-means clustering algorithm Marina Gorunescu, Florin
More informationResearch Elastography: Liver
Research Elastography: Liver Giovanna Ferraioli EFSUMB Ultrasound Learning Center Ultrasound Unit - Infectious Diseases Dept. Fondazione IRCCS Policlinico S. Matteo Medical School University of Pavia,
More informationAbstract and Introduction. Patients and Methods. M. Hedenstierna; A. Nangarhari; A. El-Sabini; O. Weiland; S.
www.medscape.com Cirrhosis, High Age and High Body Mass Index Are Risk Factors for Persisting Advanced Fibrosis After Sustained Virological Response in Chronic Hepatitis C M. Hedenstierna; A. Nangarhari;
More informationHepatocellular Carcinoma Surveillance
Amit G. Singal, MD, MS Hepatocellular Carcinoma Surveillance Postgraduate Course: Challenges in Management of Common Liver Diseases 308 1 Patient Case 69 year-old otherwise healthy male with compensated
More informationTransient elastography in chronic liver diseases of other etiologies
4 Post Meeting A.I.S.F. Unmet Clinical Needs in Hepatology: New and upcoming diagnostic tools" Transient elastography in chronic liver diseases of other etiologies Dr. Vincenza Calvaruso Gastroenterologia
More informationThe role of non-invasivemethods in evaluating liver fibrosis of patients with non-alcoholic steatohepatitis
The role of non-invasivemethods in evaluating liver fibrosis of patients with non-alcoholic steatohepatitis Objectives: Liver biopsy is the gold standard for diagnosing the extent of fibrosis in NAFLD/NASH;
More informationINHSU th International Symposium on Hepatitis Care In Substance Users
INHSU 2015 4 th International Symposium on Hepatitis Care In Substance Users Sydney, 7 October 2015 Non-invasive liver fibrosis assessment: Opportunities for enhanced liver disease assessment and treatment
More informationEvaluation of liver and spleen stiffness using a ultrasound guided method: Accuracy of ARFI(R) measurements in liver disease patients
Evaluation of liver and spleen stiffness using a ultrasound guided method: Accuracy of ARFI(R) measurements in liver disease patients Poster No.: C-3242 Congress: ECR 2010 Type: Topic: Authors: Keywords:
More informationScreening for Portal Hypertension in Cirrhosis
Screening for Portal Hypertension in Cirrhosis MASSIMO PINZANI, MD, PhD, FRCP Sheila Sherlock Chair of Hepatology UCL Institute for Liver and Digestive Health Royal Free Hospital, London, UK m.pinzani@ucl.ac.uk
More informationEvaluation of liver and spleen stiffness using a ultrasound guided method: Accuracy of ARFI(R) measurements in liver disease patients
Evaluation of liver and spleen stiffness using a ultrasound guided method: Accuracy of ARFI(R) measurements in liver disease patients Poster No.: C-3242 Congress: ECR 2010 Type: Topic: Authors: Keywords:
More informationPrediction of Hepatocellular Carcinoma Incidence Risk by Ultrasound Elastography
2235-1795/14/0031-0001$39.50/0 1 Editorial Prediction of Hepatocellular Carcinoma Incidence Risk by Ultrasound Elastography Prof. M. Kudo Editor Liver Cancer In patients with chronic hepatitis and continuous
More informationHCV care after cure. This program is supported by educational grants from
HCV care after cure This program is supported by educational grants from Raffaele Bruno,MD Department of Infectious Diseases, Hepatology Outpatients Unit University of Pavia Fondazione IRCCS Policlinico
More informationLiver stiffness predicts liver related events and mortality in HIV/HCV coinfected patients
Liver stiffness predicts liver related events and mortality in HIV/HCV coinfected patients José Vicente Fernández-Montero, Pablo Barreiro, Eugenia Vispo, Pablo Labarga, Francisco Blanco, Fernanda Rick,
More informationLong-term Clinical Outcomes and Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with HBsAg Seroclearance
Long-term Clinical Outcomes and Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with HBsAg Seroclearance Gi-Ae Kim, Han Chu Lee *, Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Young-Suk Lim,
More informationCIRROSI E IPERTENSIONE PORTALE NELLA DONNA
Cagliari, 16 settembre 2017 CIRROSI E IPERTENSIONE PORTALE NELLA DONNA Vincenza Calvaruso, MD, PhD Ricercatore di Gastroenterologia Gastroenterologia & Epatologia, Di.Bi.M.I.S. Università degli Studi di
More informationClinical Policy Title: Liver elastography
Clinical Policy Title: Liver elastography Clinical Policy Number: CCP.1118 Effective Date: October 1, 2014 Initial Review Date: June 18, 2014 Most Recent Review Date: August 7, 2018 Next Review Date: August
More informationMR Elastography of Liver
MR Elastography of Liver Sudhakar K. Venkatesh, MD, FRCR Professor of Radiology Mayo Clinic College of Medicine Consultant, Abdominal Division Radiology, Mayo Clinic Rochester, MN, USA 19 th May 2018 2018
More information1264 BOURSIER ET AL CLINICAL GASTROENTEROLOGY AND HEPATOLOGY Vol. 6, No. 11 Table 1. Study Design: Assignment of Judges According to Patient and Obser
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2008;6:1263 1269 Reproducibility of Liver Stiffness Measurement by Ultrasonographic Elastometry JÉRÔME BOURSIER,*, ANSELME KONATÉ,*, GABRIELLA GOREA,* STÉPHANE
More informationNoninvasive Diagnosis and Staging of Liver Disease. Naveen Gara, MD
Noninvasive Diagnosis and Staging of Liver Disease Naveen Gara, MD Outline Brief overview of the anatomy of liver Liver-related lab tests Chronic liver disease progression Estimation of liver fibrosis
More informationCONFOUNDING FACTORS affecting the performance of US elastography
Clinical Ultrasound in Hepatology: Training for Hepatologists UCL Institute for Liver and Digestive Health, Royal Free Hospital, London, UK June 2018 CONFOUNDING FACTORS affecting the performance of US
More informationLearning Objectives. After attending this presentation, participants will be able to:
Learning Objectives After attending this presentation, participants will be able to: Describe HCV in 2015 Describe how to diagnose advanced liver disease and cirrhosis Identify the clinical presentation
More informationHepatocellular Carcinoma: Epidemiology and Screening
Hepatocellular Carcinoma: Epidemiology and Screening W. Ray Kim, MD Professor and Chief Gastroenterology and Hepatology Stanford University School of Medicine Case A 67 year old Filipino-American woman
More informationTransient elastography (TE) (FibroScan; Echosens, Pitfalls of Liver Stiffness Measurement: A 5-Year Prospective Study of 13,369 Examinations
Pitfalls of Liver Stiffness Measurement: A 5-Year Prospective Study of 13,369 Examinations Laurent Castéra, 1,2 Juliette Foucher, 1,2 Pierre-Henri Bernard, 2 Françoise Carvalho, 1 Daniele Allaix, 1 Wassil
More informationSMJ Singapore Medical Journal
SMJ Singapore Medical Journal ONLINE FIRST PUBLICATION Online first papers have undergone full scientific review and copyediting, but have not been typeset or proofread. To cite this article, use the DOIs
More informationWhen to Treat: Staging Liver Disease David L. Thomas, MD, MPH
When to Treat: Staging Liver Disease David L. Thomas, MD, MPH Professor of Medicine Johns Hopkins School of Medicine Disclosures Received royalties from UpToDate, Inc. Staging refers to the assessment
More informationFollow-up of patients with SVR Lawrence Serfaty Service d Hépatologie, UMR_S 938 Hôpital Saint-Antoine Université Pierre&Marie Curie Paris, France
9th Paris Hepatitis Conference, January 11-12, 2016 Follow-up of patients with SVR Lawrence Serfaty Service d Hépatologie, UMR_S 938 Hôpital Saint-Antoine Université Pierre&Marie Curie Paris, France Disclosures
More informationJPGN Journal of Pediatric Gastroenterology and Nutrition Publish Ahead of Print
JPGN Journal of Pediatric Gastroenterology and Nutrition Publish Ahead of Print DOI : 10.1097/MPG.0000000000000489 Points to be considered when Applying FibroScan S Probe for Children with Biliary Atresia
More informationComparative study between two point Shear Wave Elastographic. Acoustic Radiation Force Impulse (ARFI) elastography
Original papers Med Ultrason 2014, Vol. 16, no. 4, 309-314 DOI: Comparative study between two point Shear Wave Elastographic techniques: Acoustic Radiation Force Impulse (ARFI) elastography and ElastPQ
More informationJournal of the Egyptian Society of Parasitology, Vol.46, No.1, April 2016 J. Egypt. Soc. Parasitol. (JESP), 46(1), 2016:
Journal of the Egyptian Society of Parasitology, Vol.46, No.1, April 2016 J. Egypt. Soc. Parasitol. (JESP), 46(1), 2016: 125-130 SERUM MARKERS FOR ASSESSING LIVER FIBROSIS IN EGYPTIAN PA- TIENTS WITH CHRONIC
More informationHepatology for the Nonhepatologist
Hepatology for the Nonhepatologist Kenneth E. Sherman, MD, PhD Gould Professor of Medicine Director, Division of Digestive Diseases University of Cincinnati College of Medicine Cincinnati, Ohio Learning
More informationManagement of Liver Diseases: A Nonhepatologist s Viewpoint
Management of Liver Diseases: A Nonhepatologist s Viewpoint Arthur Y. Kim, MD Associate Professor of Medicine Harvard Medical School Director, Viral Hepatitis Clinic Massachusetts General Hospital Boston,
More informationThe Impact of HBV Therapy on Fibrosis and Cirrhosis
The Impact of HBV Therapy on Fibrosis and Cirrhosis Jordan J. Feld, MD, MPH Associate Professor of Medicine University of Toronto Hepatologist Toronto Centre for Liver Disease Sandra Rotman Centre for
More informationKing Abdul-Aziz University Hospital (KAUH) is a tertiary
Modelling Factors Causing Mortality in Oesophageal Varices Patients in King Abdul Aziz University Hospital Sami Bahlas Abstract Objectives: The objective of this study is to reach a model defining factors
More informationNon-Invasive Assessment of Liver Fibrosis. Patricia Slev, PhD University of Utah Department of Pathology
Non-Invasive Assessment of Liver Fibrosis Patricia Slev, PhD University of Utah Department of Pathology Disclosure Patricia Slev has no relevant financial relationships to disclose. 2 Chronic Liver Disease
More informationHepatocellular Carcinoma: Diagnosis and Management
Hepatocellular Carcinoma: Diagnosis and Management Nizar A. Mukhtar, MD Co-director, SMC Liver Tumor Board April 30, 2016 1 Objectives Review screening/surveillance guidelines Discuss diagnostic algorithm
More informationOriginal article On-treatment monitoring of liver fibrosis with transient elastography in chronic hepatitis B patients
Antiviral Therapy 2011; 16:165 172 (doi: 10.3851/IMP1726) Original article On-treatment monitoring of liver fibrosis with transient elastography in chronic hepatitis B patients Grace Lai-Hung Wong 1,2,
More informationNon-invasive diagnosis of hepatitis B virus-related cirrhosis
Online Submissions: http://www.wjgnet.com/esps/ bpgoffice@wjgnet.com doi:10.3748/wjg.v20.i2.445 World J Gastroenterol 2014 January 14; 20(2): 445-459 ISSN 1007-9327 (print) ISSN 2219-2840 (online) 2014
More informationClinical Criteria for Hepatitis C (HCV) Therapy
Clinical Criteria for Hepatitis C (HCV) Therapy Pre-Treatment Evaluation o Must have chronic hepatitis C and HCV genotype and sub-genotype documented; o Patients who have prior exposure to DAA therapy
More informationHepatocytes produce. Proteins Clotting factors Hormones. Bile Flow
R.J.Bailey MD Hepatocytes produce Proteins Clotting factors Hormones Bile Flow Trouble.. for the liver! Trouble for the Liver Liver Gall Bladder Common Alcohol Hep C Fatty Liver Cancer Drugs Viruses Uncommon
More informationUNIVERSA MEDICINA. Forns index as a useful noninvasive predictor of esophageal varices in liver cirrhosis
UNIVERSA MEDICINA September-December, 2016 Vol.35 - No.3 Forns index as a useful noninvasive predictor of esophageal varices in liver cirrhosis Rizqi Arini Siregar*, Leonardo B. Dairi*, and Gontar Alamsyah
More informationIs exposure to Agent Orange a risk factor for hepatocellular cancer? A single-center retrospective study in the U.S. veteran population
Original Article Is exposure to Agent Orange a risk factor for hepatocellular cancer? A single-center retrospective study in the U.S. veteran population Padmini Krishnamurthy, Nyla Hazratjee, Dan Opris,
More informationOriginal papers Med Ultrason 2013, Vol. 15, no. 4,
Original papers Med Ultrason 2013, Vol. 15, no. 4, 268-272 DOI: How many measurements are needed for liver stiffness assessment by 2D-Shear Wave Elastography (2D-SWE) and which value should be used: the
More informationHepatitis Alert: Management of Patients With HCV Who Have Achieved SVR
Hepatitis Alert: Management of Patients With HCV Who Have Achieved SVR This program is supported by educational grants from AbbVie, Gilead Sciences, and Merck About These Slides Please feel free to use,
More informationComparison of transient elastography to Doppler indices in prediction of hepatitis C induced liver fibrosis and cirrhosis
The Egyptian Journal of Radiology and Nuclear Medicine (2011) 42, 111 117 Egyptian Society of Radiology and Nuclear Medicine The Egyptian Journal of Radiology and Nuclear Medicine www.elsevier.com/locate/ejrnm
More informationImproved Hepatic Fibrosis Grading Using Point Shear Wave Elastography and Machine Learning
Improved Hepatic Fibrosis Grading Using Point Shear Wave Elastography and Machine Learning Presenter: Hersh Sagreiya 1, M.D. Authors: Alireza Akhbardeh 1, Ph.D., Isabelle Durot 1, M.D., Carlo Filice 2,
More informationHow useful are ARFI elastography cut-off values proposed by metaanalysis for predicting the significant fibrosis and compensated liver cirrhosis?
Original papers Med Ultrason 2015, Vol. 17, no. 2, 200-205 DOI: 10.11152/mu.2013.2066.172.arfi How useful are ARFI elastography cut-off values proposed by metaanalysis for predicting the significant fibrosis
More informationNew York State HCV Provider Webinar Series
New York State HCV Provider Webinar Series Overview of Fibrosis-Staging, Child s Pugh, MELD Scores Paul J Gaglio, MD, FACP, AGAF, FAASLD Director: Hepatology Outreach Professor of Medicine (in Surgery)
More informationNONINVASIVE IMAGING METHODS FOR ASSESSMENT OF LIVER DAMAGE IN NASH
NONINVASIVE IMAGING METHODS FOR ASSESSMENT OF LIVER DAMAGE IN NASH Bachir Taouli, MD Director of Body MRI and Cancer Imaging Program Department of Radiology / Translational and Molecular Imaging Institute
More informationDIAGNOSIS OF CIRRHOSIS BY TRANSIENT ELASTOGRAPHY (FIBROSCAN ): A PROSPECTIVE STUDY.
Gut Online First, published on July 14, 2005 as 10.1136/gut.2005.069153 DIAGNOSIS OF CIRRHOSIS BY TRANSIENT ELASTOGRAPHY (FIBROSCAN ): A PROSPECTIVE STUDY. Juliette Foucher (1), Elise Chanteloup (1), Julien
More informationOriginal Article. Six Month Follow-up of Liver Stiffness Measurement in Untreated Chronic Hepatitis C With or Without HIV Co-infection
Original Article Phrommee N, et al. 15 Six Month Follow-up of Liver Stiffness Measurement in Untreated Chronic Hepatitis C With or Without HIV Co-infection Phrommee N Leerapun A Pisespongsa P Chitapanarux
More informationClinical Policy Title: Noninvasive assessment of hepatic fibrosis
Clinical Policy Title: Noninvasive assessment of hepatic fibrosis Clinical Policy Number: 08.01.03 Effective Date: Oct. 1, 2014 Initial Review Date: June 18, 2014 Most Recent Review Date: August 17, 2017
More information3 Workshop on HCV THERAPY ADVANCES New Antivirals in Clinical Practice
3 Workshop on HCV THERAPY ADVANCES New Antivirals in Clinical Practice Rome, 13 December 2013 Management and monitoring of HCC in the future era of DAA s Prof. Massimo Colombo Chairman Department of Liver,
More informationXiao-Ping Ye, MM, Hai-Tao Ran, MD, Juan Cheng, MM, Ye-Feng Zhu, MM, Da-Zhi Zhang, MD, Ping Zhang, MD, Yuan-Yi Zheng, MD
ORIGINAL RESEARCH Liver and Spleen Stiffness Measured by Acoustic Radiation Force Impulse Elastography for Noninvasive Assessment of Liver Fibrosis and Esophageal Varices in Patients With Chronic Hepatitis
More informationEASL-EORTC Guidelines
Pamplona, junio de 2008 CLINICAL PRACTICE GUIDELINES: PARADIGMS IN MANAGEMENT OF HCC EASL-EORTC Guidelines Bruno Sangro Clínica Universidad de Navarra. CIBERehd. Pamplona, Spain Levels of Evidence according
More informationWHEN HCV TREATMENT IS DEFERRED WV HEPC ECHO PROJECT
WHEN HCV TREATMENT IS DEFERRED WV HEPC ECHO PROJECT October 13, 2016 Reminder - treatment is recommended for all patients with chronic HCV infection Except short life expectancies that cannot be remediated
More informationRole of Transient Elastography in Early Detection of HCC in Cirrhotic Patients
159 Role of Transient Elastography in Early Detection of HCC in Cirrhotic Patients Abdel Ghani Atef Badran 1, Naglaa El-Tokhy Ramadan El-Tokhy 2, Seham Mohamad Seif 3 and Hossam Amin Baioumy 2 1 Liver
More informationPerformance of 2D-SWE.GE for predicting different stages of liver fibrosis, using Transient Elastography as the reference method
Original papers Med Ultrason 2017, Vol. 19, no. 2, 143-149 DOI: 10.11152/mu-910 Performance of 2D-SWE.GE for predicting different stages of liver fibrosis, using Transient Elastography as the reference
More informationFunctional liver imaging Bernard Van Beers
Functional liver imaging Bernard Van Beers Department of Radiology Beaujon University Hospital Paris Nord Laboratory of Imaging biomarkers UMR 1149 Inserm - University Paris Diderot France Functional imaging
More informationNon-invasive assessment of liver fibrosis in chronic hepatitis B
Submit a Manuscript: http://www.wjgnet.com/esps/ Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx DOI: 10.3748/wjg.v20.i40.14568 World J Gastroenterol 2014 October 28; 20(40): 14568-14580 ISSN 1007-9327
More informationAssessment of Liver Stiffness by Transient Elastography in Diabetics with Fatty Liver A Single Center Cross Sectional observational Study
IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 2279-0853, p-issn: 2279-0861.Volume 16, Issue 6 Ver. IV (June. 2017), PP 49-53 www.iosrjournals.org Assessment of Liver Stiffness by Transient
More informationEuropean. Young Hepatologists Workshop. Organized by : Quantification of fibrosis and cirrhosis outcomes
supported by from Gilea Quantification of fibrosis and cirrhosis outcomes th 5 European 5 European Young Hepatologists Workshop Young Hepatologists Workshop August, 27-29. 2015, Moulin de Vernègues Vincenza
More informationRelationship between Controlled Attenuation Parameter and Hepatic Steatosis as Assessed by Ultrasound in Alcoholic or Nonalcoholic Fatty Liver Disease
Gut and Liver, Vol. 10, No. 2, March 2016, pp. 295-302 ORiginal Article Relationship between Controlled Attenuation Parameter and Hepatic Steatosis as Assessed by Ultrasound in Alcoholic or Nonalcoholic
More informationClinical Criteria for Hepatitis C (HCV) Therapy
Clinical Criteria for Hepatitis C (HCV) Therapy Pre-Treatment Evaluation o Must have chronic hepatitis C and HCV genotype and sub-genotype documented; o Patients who have prior exposure to DAA therapy
More informationHow to apply HCC prediction models to practice?
How to apply HCC prediction models to practice? Department of Internal Medicine, Keimyung University School of Medicine Woo Jin Chung HCC prediction models 독특하게간세포암환자들의생존은암의진행상태뿐아니라기저간기능의중증정도에영향을받는특성이있다.
More informationInitial Evaluation for HCV Therapy. Hope McGratty PA-C, MPH
Initial Evaluation for HCV Therapy Hope McGratty PA-C, MPH Conflict of Interest Disclosure Statement None Who are we talking about today? Treatment naïve Chronic infection This patient seems complicated
More informationModule 1 Introduction of hepatitis
Module 1 Introduction of hepatitis 1 Training Objectives At the end of the module, trainees will be able to ; Demonstrate improved knowledge of the global epidemiology of the viral hepatitis Understand
More informationThe evaluation of liver fibrosis is a key step to manage
GASTROENTEROLOGY 2011;140:1970 1979 CLINICAL LIVER, BILIARY TRACT Noninvasive Tests for Fibrosis and Liver Stiffness Predict 5-Year Outcomes of Patients With Chronic Hepatitis C JULIEN VERGNIOL,* JULIETTE
More informationUltrasound screening for hepatocellular carcinoma in patients with advanced liver fibrosis. An overview.
Review Med Ultrason 2014, Vol. 16, no. 2, 139-144 DOI: Ultrasound screening for hepatocellular carcinoma in patients with advanced liver fibrosis. An overview. Mirela Dănilă, Ioan Sporea Gastroenterology
More informationNON INVASIVE EVALUATION OF DISEASE PROGRESSION IN CHRONIC LIVER DISEASES
Best of EASL -, Ethiopia 29 Sep to 01 Oct, 2016 Inaugural meeting of the Sub Saharan GI-Hepatology Working Group Incorporating Best of AGA and Best of EASL NON INVASIVE EVALUATION OF DISEASE PROGRESSION
More informationHEPATOCELLULAR CARCINOMA: SCREENING, DIAGNOSIS, AND TREATMENT
HEPATOCELLULAR CARCINOMA: SCREENING, DIAGNOSIS, AND TREATMENT INTRODUCTION: Hepatocellular carcinoma (HCC): Fifth most common cancer worldwide Third most common cause of cancer mortality In Egypt: 2.3%
More informationHepatocellular Carcinoma. Markus Heim Basel
Hepatocellular Carcinoma Markus Heim Basel Outline 1. Epidemiology 2. Surveillance 3. (Diagnosis) 4. Staging 5. Treatment Epidemiology of HCC Worldwide, liver cancer is the sixth most common cancer (749
More informationTransient Elastography (Fibroscan) Compared to Diagnostic Endoscopy in the Diagnosis of Varices in Patients with Cirrhosis
Science Journal of Clinical Medicine 2016; 5(6): 55-59 http://www.sciencepublishinggroup.com/j/sjcm doi: 10.11648/j.sjcm.20160506.13 ISSN: 2327-2724 (Print); ISSN: 2327-2732 (Online) Transient Elastography
More informationLiver Disease Assessment Among PWID: The Role of Transient Elastography
Liver Disease Assessment Among PWID: The Role of Transient Elastography Peer Brehm Christensen, Professor Department of Infectious Diseases Odense University Hospital Denmark Peer.christensen@dadlnet.dk
More informationLiver Biopsy and FibroScan to Detect Early Histopathological Changes in Chronic HBV Patients Not Candidate for Treatment
Original Article Elmer Press Liver Biopsy and FibroScan to Detect Early Histopathological Changes in Chronic HBV Patients Not Candidate for Treatment Sahar Maklad a, Gamal Esmat b, Ehsan Hassan c, Mohamed
More informationLiver resection for HCC
8 th LIVER INTEREST GROUP Annual Meeting Cape Town 2017 Liver resection for HCC Jose Ramos University of the Witwatersrand Donald Gordon Medical Centre The liver is almost unique in that treatment of the
More informationNew Tools for Assessing Disease Sererity, progression and regression in HBV and HCV
New Tools for Assessing Disease Sererity, progression and regression in HBV and HCV Jidong Jia, MD, PhD Beijing Friendship Hospital, Capital Medical University 2016-3-14 Disclosure Consultation for Abbvie
More informationFactors Influencing the Diagnostic Accuracy of Acoustic Radiation Force Impulse Elastography in Patients with Chronic Hepatitis B
Gut and Liver, Vol. 1, No. 2, March 216, pp. 275-282 ORiginal Article Factors Influencing the Diagnostic Accuracy of Acoustic Radiation Force Impulse Elastography in Patients with Chronic Hepatitis B Mi
More informationJournal of Antimicrobial Chemotherapy Advance Access published April 25, 2013
Journal of Antimicrobial Chemotherapy Advance Access published April 25, 213 J Antimicrob Chemother doi:1.193/jac/dkt147 Virological response to entecavir reduces the risk of liver disease progression
More informationClinical Criteria for Hepatitis C (HCV) Therapy
Clinical Criteria for Hepatitis C (HCV) Therapy Pre-Treatment Evaluation o Must have chronic hepatitis C and HCV genotype and sub-genotype documented; o Patients who have prior exposure to DAA therapy
More informationGamal F. El Naggar (1), Eman A. Alzamarany (2)
Diagnostic value of Protein Induced by Vitamin K Absence or Antagonist - II (PIVIKA II) in patients with hepatocellular carcinoma (HCC): Comparison with alpha fetoprotein Gamal F. El Naggar (1), Eman A.
More informationThe New World of HCV Therapy
HCV: Assessing the Patient Prior to Treatment: Diagnostic Testing and Strategy JORGE L. HERRERA, MD, MACG UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE, MOBILE, AL The New World of HCV Therapy Interferon-free
More informationAspartate aminotransferase-to-platelet ratio index in children with cholestatic liver diseases to assess liver fibrosis
The Turkish Journal of Pediatrics 2015; 57: 492-497 Original Aspartate aminotransferase-to-platelet ratio index in children with cholestatic liver diseases to assess liver fibrosis Aysel Ünlüsoy-Aksu 1,
More informationHEP DART 2017, Kona, Hawaii
HEP DART 2017, Kona, Hawaii Rong Yu 1, Ke Xu 1, Jing Li 1, Tong Sun 1, Shengjiang Zhang 2, Jinhua Shao 2, Jin Sun 2, Qiong He 3, Jianwen Luo 3, Cheng Wang 4, Yudong Wang 4, Jing Chen 4, Vanessa Wu 4, George
More informationIS THERE A DIFFERENCE IN LIVER CANCER RATES IN PATIENTS WHO RECEIVE TREATMENT FOR HEPATITIS?
IS THERE A DIFFERENCE IN LIVER CANCER RATES IN PATIENTS WHO RECEIVE TREATMENT FOR HEPATITIS? Dr. Sammy Saab David Geffen School of Medicine, Los Angeles, USA April 2018 DISCLAIMER Please note: The views
More informationHepatology For The Nonhepatologist
Hepatology For The Nonhepatologist Andrew Aronsohn, MD Associate Professor of Medicine University of Chicago Chicago, Illinois Learning Objectives After attending this presentation, learners will be able
More information